118431-89-3

Usage

Uses

Used in Pharmaceutical Industry:
3-CYCLOBUTYL-3-OXO-PROPIONITRILE is utilized as a key building block in the synthesis of various pharmaceuticals. Its role in drug development is crucial, as it contributes to the creation of new medications and therapeutic agents.
Used in Agrochemical Production:
3-CYCLOBUTYL-3-OXO-PROPIONITRILE also finds application in the agrochemical sector, where it is employed in the production of different agrochemicals. Its use in this industry aids in the development of agricultural products that can enhance crop protection and yield.
Used as an Intermediate in Chemical Manufacturing:
3-CYCLOBUTYL-3-OXO-PROPIONITRILE serves as an intermediate in the manufacturing process of other chemicals. Its presence in the synthesis chain is essential for the production of a range of chemical products.
Used as a Reagent in Organic Reactions:
In the context of organic chemistry, 3-CYCLOBUTYL-3-OXO-PROPIONITRILE is used as a reagent, facilitating various organic reactions. Its reactivity makes it a valuable component in the synthesis of complex organic molecules.
Safety Considerations:
Due to its toxic and potentially hazardous nature, 3-CYCLOBUTYL-3-OXO-PROPIONITRILE must be handled with caution. Proper safety measures should be implemented to minimize risks associated with its use in research and industrial applications.

Upstream product

• 403595-50-6 2-cyano-3-cyclobutyl-3-oxo-propionic acid ethyl ester 
• 140-69-2 4-methoxybenzylhydrazine 
• 14924-53-9 ethyl cyclobutylcarboxylate 
• 75-05-8 acetonitrile 
• 765-85-5 methyl cyclobutanecarboxylate 

Downstream Products

• 92406-41-2 3-cyclobutyl-1-methyl-1H-pyrazol-5-amine 
• 92388-32-4 4,7-dihydro-1,6-dimethyl-4-(3-nitrophenyl)-3-(cyclobutyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid methyl ester 
• 326827-21-8 5-cyclobutyl-3-amino-1H-pyrazole 
• 817641-86-4 1-tert-butyl-3-cyclobutyl-1H-pyrazol-5-amine 
• 1229454-63-0 5-cyclobutylisoxazol-3-ylamine 

Relevant academic research and scientific papers

INHIBITORS OF TYROSINE KINASE

The present disclosure provides compounds and compositions thereof which are useful as inhibitors of tyrosine kinase and which exhibit desirable characteristics for the same. Further disclosed herein are methods of treating cancer using these tyrosine kin

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF KIDNEY DISEASES

The present invention discloses compounds according to Formula I: (l) Wherein R1 is as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of that may be useful in the prophylaxis and/or treatment of polycystic kidney disease (PKD), by administering the compound of the invention.

Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy

We synthesized a library of aminopyrazole analogs to systematically explore the hydrophobic pocket adjacent to the hinge region and the solvent exposed region of cyclin dependent kinases. Structure-activity relationship studies identified an optimal substitution for the hydrophobic pocket and analog 24 as a potent and selective CDK2/5 inhibitor.

N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

A reliable synthesis of 3-amino-5-alkyl and 5-amino-3-alkyl isoxazoles

A reliable procedure that can be used to access a wide range of 3-amino-5-alkyl and 5-amino-3-alkyl isoxazoles was developed. Reaction temperature and pH were key factors that determined the regioselectivity of the two reactions.

Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

NEW ARYL-QUINOLINE DERIVATIVES

The invention provides novel compounds having the general formula (I), wherein R1, R2, R3, R4 R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds.

ARYL-QUINOLINE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.